Delta Life Science is a biotechnology startup based in The Netherlands, founded in 2018. The company's mission is to make label-free, multiplexed biosensing accessible to all. It offers rapid, highly sensitive, and low-cost biosensing, catering to various needs across different industries.
Unlike most platforms that focus solely on sensitivity, multiplexing, or cost, Delta Life Science provides all three. By leveraging photonic integrated circuits, the company accelerates research by a factor of 4 and reduces ownership costs by a factor of 5, making label-free biosensing accessible to every researcher.
The company's innovative approach benefits a wide range of applications, including studying molecular interactions, accelerating drug kinetics-screening, and developing real-time quantitative biomarker assays. As a spinoff of TNO, Delta Life Science develops integrated photonics to create highly sensitive and selective biosensors, making them an order of magnitude more affordable and capable of measuring multiple biomarkers and reaching SPR sensitivity.
With its recent €5.25M Series A investment received on 09 May 2023 from InnovationQuarter, Oost NL, PhotonDelta, and i&i Biotech Fund, Delta Life Science is well-positioned to further develop its technologies and expand its market presence.
The company's innovative biosensing technology has the potential to significantly impact various sectors, from medical research to Point-of-Care diagnostic applications.